Around this time of year, everyone writes about forecasts and trends. The article provides an eagle-eyed view of the evolving landscape of the healthcare industry. We will look at key health trends from 2018 and upcoming challenges and opportunities to keep in mind for 2019. With each passing year, technological advancements affect different fields, and so does the health industry. Healthcare is marked with different growth patterns and trends that vary across its different sub-domains. This example involves multivariate growth of some domains, which contrasts with inconsistent stability in others.
1. Diagnostics will have a Patient-Centric Approach
With the radical change of expectations that a customer has today, the need for consumer inclusion in the business model is increasing to an appreciable extent. When it comes to the diagnostic aspect of patient care, the need for consumerism in consumerism is not expected to be sufficient. Thus, diagnostic entities are adopting best practices to stay ahead in the value-based system.
Major pharma players are also investing in consumer genetics for the development of novel pharmaceutical products.
In this regard, GlaxoSmithKline entered into a four-year collaboration with 23 and May; One of the leading players in the genetic testing market; For drug discovery through human genetics.
Based on comprehensive strategies such as consumer genomics and precision, clinical decision-making is expected to provide a simple, standardized, effective and efficient patient experience across the care spectrum focusing on prevention, illness, and long-term health. Medicine.
2. Gene Editing Technologies will Advance
Gene editing technology in diagnostic platforms disease Geo 2019 and beyond is set to change the face of disease detection, biosensing, and diagnostics. Moreover, it can be equally effective in the fields of agriculture, bio-production, and forensics.
CRISPR can transform the utility of complex laboratory-based disease diagnostics tests into in-house diagnostic kits that are as easy to operate as a pregnancy detection kit. Thus, it can serve as a simple point-of-care solution for the diagnosis of complex disorders.
In mid-2018, Mammoth Bioscience launched the first CRISPR-based diagnostic platform of its kind to detect diseases.
Similar developments are expected along the year 2019 as the platform can easily be programmed to locate a wide range of DNA- or RNA-based targets. Thus, CRISPR-based diagnostics is expected to intensify with the discovery of more and more biomarkers in the future.
CRISPR applications are spread across almost every area that is based on a biological system that includes food, laboratory and medical applications. Given the scope of such a wide range of CRISPR / KS9 technologies across multiple industries, this genome acquisition method is estimated to stimulate significant economic activity for the launch of novel agricultural and industrial applications.
However, CRISPR still needs to overcome the controversy surrounding the concept of ‘man-made’ mutations in the human genome, except for ongoing patent litigation and infringement claims. Moreover, in order to weaken the patient’s ability to fight the tumor, it is necessary to address the safety concerns resolved in 2018, over the CIRPR by Novartis and the Karolinska Institute.
3. Exosomes will be seen as Potential Targeted Therapy
Additionally, exosome-mediated transport plays an important role in epithelial-mesenchymal transition (EMT) signaling, angiogenesis, and various mechanisms such as metastasis and hypoxia because exosomes exhibit anti or proteome reagent properties.
Exosomes can promote or suppress cancer growth through a variety of intercellular communication within the microenvironment of the tumor, due to its antagonistic or proteome or regenic properties.
The potential applications of exosomes to solve drug delivery problems for signals such as RNA therapy, viral gene therapy, and small molecules as well as CRISPR gene-editing tools are still being studied.
Moreover, recent studies also show that exosomes, when taken from stem cells, are used as regenerative medicine.
Further research related to exosome detection and secretion will support the development of novel diagnostic, therapeutic and preventive approaches, as well as targeting specific cancer cells.
However, some of the risks associated with use are expected to reduce the unsafe consumption of these treatments, which has been increasing in recent years. With the explosion of stem cell exosome research into translation drugs, a proven way of clinically accredited trials will serve as a green flag for exosome derived products.